Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by Wall Street Zen to Buy

Wall Street Zen cut shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a strong-buy rating to a buy rating in a research note released on Sunday.

TEVA has been the subject of a number of other reports. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. The Goldman Sachs Group increased their price target on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Barclays assumed coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $33.67.

Teva Pharmaceutical Industries Trading Down 1.8%

TEVA opened at $31.78 on Friday. The firm’s 50 day moving average is $29.00 and its 200-day moving average is $22.15. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $33.42. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The firm has a market capitalization of $36.45 billion, a P/E ratio of 52.97, a P/E/G ratio of 1.82 and a beta of 0.66.

Insider Transactions at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 12,300 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares in the company, valued at $170,630. This represents a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president directly owned 48,384 shares in the company, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 622,060 shares of company stock valued at $17,076,965. Company insiders own 0.49% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. Grove Bank & Trust increased its holdings in shares of Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares during the period. Cromwell Holdings LLC lifted its stake in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $41,000. Rothschild Investment LLC boosted its holdings in Teva Pharmaceutical Industries by 97.0% during the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after buying an additional 1,348 shares in the last quarter. Finally, JFS Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 257.1% in the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after buying an additional 2,000 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.